美国绝经后女性骨质疏松筛查中椎体骨折评估(VFA)的成本效益分析
本研究采用个体水平状态转移成本效益模型,从医疗保健视角评估椎体骨折评估(VFA)作为美国≥65岁社区居住女性骨质疏松筛查工具的成本效益。结果显示,在双能X线吸收检测(DXA)基础上结合VFA可略微提高预期寿命、减少后续骨质疏松性骨折,并节省费用,支持美国国家骨质疏松基金会(NOF)关于VFA作为骨折风险评估重要补充的诊断应用指南。
要点
- 对≥65岁女性,DXA后若股骨颈T值≤-1.0再行VFA最具成本效益。
- VFA纳入常规筛查可略微提高预期寿命并减少后续骨质疏松性骨折。
- 研究结果支持NOF指南将VFA作为骨折风险评估的重要补充。
核心结论
- 在≥65岁女性中,将VFA纳入常规骨质疏松筛查具有成本效益。
- 研究结果支持美国国家骨质疏松基金会(NOF)关于VFA作为骨折风险评估重要补充的诊断应用指南。
研究设计与样本
- 构建个体水平状态转移成本效益模型,从医疗保健视角出发,数据来源于已发表文献。
- 时间范围为终生,比较五种筛查策略:不筛查、仅中心DXA、仅VFA、中心DXA后若股骨颈T值≤-1.5再行VFA、中心DXA后若股骨颈T值≤-1.0再行VFA。
- 评估了不同的起始年龄和复查间隔,假设口服双膦酸盐治疗5年。
- 结局指标为增量成本效益比(2017年美元/获得的质量调整生命年)。
主要发现
- 与单独使用DXA相比,纳入VFA使预期寿命略微增加0.1年,后续骨质疏松性骨折减少3.7%。
- 无论起始年龄和复查间隔如何,中心DXA后若股骨颈T值≤-1.0再行VFA最具成本效益(65岁开始筛查且每5年复查时,为40,792美元/质量调整生命年)。
- 结果对椎体骨折发生率和药物成本的变化具有稳健性。
关键数值与推荐
- 中心DXA后若股骨颈T值≤-1.0再行VFA最具成本效益,65岁开始筛查且每5年复查时成本为40,792美元/质量调整生命年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Vertebral fracture assessment (VFA) is cost-effective when it was incorporated in the routine screening for osteoporosis in community-dwelling women aged ≥ 65 years, which support guidelines, such as the National Osteoporosis Foundation (NOF) for the diagnostic use of VFA as an important addition to fracture risk assessment. INTRODUCTION: To evaluate the cost-effectiveness of VFA as a screening tool to reduce future fracture risk in US community-dwelling women aged ≥ 65 years. METHODS: An individual-level state-transition cost-effectiveness model from a healthcare perspective was constructed using derived data from published literature. The time horizon was lifetime. Five screening strategies were compared, including no screening at all, central dual-energy X-ray absorptiometry (DXA) only, VFA only, central DXA followed by VFA if the femoral neck T-score (FN-T) ≤ - 1.5, or if the FN-T ≤ - 1.0. Various initiation ages and rescreening intervals were evaluated. Oral bisphosphonate treatment for 5-year periods was assumed. Incremental cost-effectiveness ratios (2017 US dollars per quality-adjusted life-year (QALY) gained) were used as the outcome measure. RESULTS: The incorporation of VFA slightly increased life expectancy by 0.1 years and reduced the number of subsequent osteoporotic fractures by 3.7% and 7.7% compared with using DXA alone and no screening, respectively, leading to approximately 30 billion dollars saved. Regardless of initiation ages and rescreening intervals, central DXA followed by VFA if the FN-T ≤ - 1.0 was most cost-effective ($40,792 per QALY when the screening is initiated at age 65 years and with rescreening every 5 years). Results were robust to change in VF incidence and medication costs. CONCLUSION: In women aged ≥ 65 years, VFA is cost-effective when it was incorporated in routine screening for osteoporosis. Our findings support the National Osteoporosis Foundation (NOF) guidelines for the diagnostic use of VFA as an important addition to fracture risk assessment.
引用
- Yang J, Cosman F, Stone PW, et al. Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective? Osteoporos Int. 2020. PMID: 32778935. doi:10.1007/s00198-020-05588-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。